JP7037186B2 - 加齢黄斑変性のための高用量スタチン - Google Patents

加齢黄斑変性のための高用量スタチン Download PDF

Info

Publication number
JP7037186B2
JP7037186B2 JP2018519309A JP2018519309A JP7037186B2 JP 7037186 B2 JP7037186 B2 JP 7037186B2 JP 2018519309 A JP2018519309 A JP 2018519309A JP 2018519309 A JP2018519309 A JP 2018519309A JP 7037186 B2 JP7037186 B2 JP 7037186B2
Authority
JP
Japan
Prior art keywords
patient
amd
pharmaceutical composition
prevention
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018519309A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018530586A5 (enExample
JP2018530586A (ja
Inventor
ババス，デミトリオス
ミラー，ジョーン・ダブリュ
Original Assignee
マサチューセッツ・アイ・アンド・イア・インファーマリー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マサチューセッツ・アイ・アンド・イア・インファーマリー filed Critical マサチューセッツ・アイ・アンド・イア・インファーマリー
Publication of JP2018530586A publication Critical patent/JP2018530586A/ja
Publication of JP2018530586A5 publication Critical patent/JP2018530586A5/ja
Priority to JP2021147620A priority Critical patent/JP7754480B2/ja
Application granted granted Critical
Publication of JP7037186B2 publication Critical patent/JP7037186B2/ja
Priority to JP2023177353A priority patent/JP2024016045A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2018519309A 2015-10-14 2016-10-14 加齢黄斑変性のための高用量スタチン Active JP7037186B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021147620A JP7754480B2 (ja) 2015-10-14 2021-09-10 加齢黄斑変性のための高用量スタチン
JP2023177353A JP2024016045A (ja) 2015-10-14 2023-10-13 加齢黄斑変性のための高用量スタチン

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562241522P 2015-10-14 2015-10-14
US62/241,522 2015-10-14
PCT/US2016/056987 WO2017066529A1 (en) 2015-10-14 2016-10-14 High-dose statins for age-related macular degeneration

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021147620A Division JP7754480B2 (ja) 2015-10-14 2021-09-10 加齢黄斑変性のための高用量スタチン

Publications (3)

Publication Number Publication Date
JP2018530586A JP2018530586A (ja) 2018-10-18
JP2018530586A5 JP2018530586A5 (enExample) 2019-11-21
JP7037186B2 true JP7037186B2 (ja) 2022-03-16

Family

ID=58517927

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018519309A Active JP7037186B2 (ja) 2015-10-14 2016-10-14 加齢黄斑変性のための高用量スタチン
JP2021147620A Active JP7754480B2 (ja) 2015-10-14 2021-09-10 加齢黄斑変性のための高用量スタチン
JP2023177353A Withdrawn JP2024016045A (ja) 2015-10-14 2023-10-13 加齢黄斑変性のための高用量スタチン

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021147620A Active JP7754480B2 (ja) 2015-10-14 2021-09-10 加齢黄斑変性のための高用量スタチン
JP2023177353A Withdrawn JP2024016045A (ja) 2015-10-14 2023-10-13 加齢黄斑変性のための高用量スタチン

Country Status (13)

Country Link
US (2) US11331295B2 (enExample)
EP (1) EP3362063B1 (enExample)
JP (3) JP7037186B2 (enExample)
AU (1) AU2016338540B2 (enExample)
CA (1) CA3001661C (enExample)
DK (1) DK3362063T3 (enExample)
ES (1) ES2941347T3 (enExample)
FI (1) FI3362063T3 (enExample)
IL (1) IL258604B2 (enExample)
MX (1) MX391944B (enExample)
PH (1) PH12018500745B1 (enExample)
WO (1) WO2017066529A1 (enExample)
ZA (1) ZA201803097B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11789024B2 (en) 2017-05-09 2023-10-17 Massachusetts Eye And Ear Infirmary Biomarkers for age-related macular degeneration
WO2019018350A1 (en) * 2017-07-17 2019-01-24 Keith Roizman TOPICAL ADMINISTRATION OF THERAPEUTIC AGENTS COMPRISING CELL PENETRATION PEPTIDES, FOR USE IN THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND OTHER OCULAR DISEASES
US20200243170A1 (en) * 2017-10-17 2020-07-30 Apeliotus Technologies, Inc. Functional biomarkers for statin therapy in age-related macular degeneration (amd)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050250745A1 (en) 2004-02-25 2005-11-10 Seddon Johanna M Biomarkers for age-related macular degeneration (AMD)
US20110020237A1 (en) 2005-01-14 2011-01-27 Glabe Charles G Compositions and Methods for Inhibiting Drusen Formation and for Diagnosing or Treating Drusen-Related Disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030065020A1 (en) * 2001-07-13 2003-04-03 Catharine Gale Treatment of macular degeneration
CA2478317A1 (en) 2002-03-04 2003-09-18 Medimmune, Inc. Methods of preventing or treating disorders by administering an integrin .alpha.v.beta.3 antagonist in combination with an hmg-coa reductase inhibitor or a bisphosphonate
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
WO2008006535A2 (en) 2006-07-10 2008-01-17 Medigene Ag Use of a cationic colloidal preparation for the diagnosis and treatment of ocular diseases
JP2008268506A (ja) * 2007-04-19 2008-11-06 Fuji Xerox Co Ltd 現像装置、像保持体ユニットおよび画像形成装置
WO2009023411A1 (en) 2007-08-09 2009-02-19 Bausch & Lomb Incorporated Compositions and methods for treating or controlling anterior- and posterior-segment ophthalmic diseases
US20120156202A1 (en) 2010-11-05 2012-06-21 Shantha Totada R Age related macular degeneration treatment
ES2947557T3 (es) 2013-09-06 2023-08-11 Vanda Pharmaceuticals Inc Tratamiento de afecciones mediadas por CYR61 y VEGF
WO2016009430A1 (en) 2014-07-14 2016-01-21 Yeda Research And Development Co. Ltd Reduction of aging-induced type i interferon signaling at the brain's choroid plexus or within the cns for treatment of disease or injury of the cns
CA2954475C (en) 2014-07-31 2023-05-16 Uab Research Foundation Apoe mimetic peptides and higher potency to clear plasma cholesterol

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050250745A1 (en) 2004-02-25 2005-11-10 Seddon Johanna M Biomarkers for age-related macular degeneration (AMD)
US20110020237A1 (en) 2005-01-14 2011-01-27 Glabe Charles G Compositions and Methods for Inhibiting Drusen Formation and for Diagnosing or Treating Drusen-Related Disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EYE，2014年02月07日，vol. 28, no. 4，p. 472-480
PLOS ONE，2013年12月31日，vol. 8, no. 12, e83759，p. 1-10

Also Published As

Publication number Publication date
CA3001661A1 (en) 2017-04-20
DK3362063T3 (da) 2023-04-03
EP3362063A4 (en) 2019-06-19
PH12018500745B1 (en) 2023-03-15
AU2016338540A1 (en) 2018-05-24
EP3362063A1 (en) 2018-08-22
AU2016338540B2 (en) 2022-04-28
US20190209522A1 (en) 2019-07-11
JP2024016045A (ja) 2024-02-06
IL258604B1 (en) 2024-05-01
US11331295B2 (en) 2022-05-17
ZA201803097B (en) 2022-12-21
EP3362063B1 (en) 2023-01-11
NZ742203A (en) 2025-06-27
JP7754480B2 (ja) 2025-10-15
MX2018004636A (es) 2019-06-20
JP2022003042A (ja) 2022-01-11
IL258604B2 (en) 2024-09-01
US11744817B2 (en) 2023-09-05
WO2017066529A1 (en) 2017-04-20
JP2018530586A (ja) 2018-10-18
US20210077457A1 (en) 2021-03-18
ES2941347T3 (es) 2023-05-22
IL258604A (en) 2018-06-28
FI3362063T3 (fi) 2023-04-06
PH12018500745A1 (en) 2018-10-15
MX391944B (es) 2025-03-21
CA3001661C (en) 2025-05-06

Similar Documents

Publication Publication Date Title
US11517572B2 (en) Killing senescent cells and treating senescence-associated conditions using a SRC inhibitor and a flavonoid
JP2024016045A (ja) 加齢黄斑変性のための高用量スタチン
Holz et al. Geographic atrophy: clinical features and potential therapeutic approaches
de Paiva et al. Resolvin E1 (RX-10001) reduces corneal epithelial barrier disruption and protects against goblet cell loss in a murine model of dry eye
RU2444356C2 (ru) Полиненасыщенные жирные кислоты для лечения деменции и состояний, связанных с преддеменцией
US20100087474A1 (en) Materials and methods for enhanced degradation of mutant proteins associated with human disease
US10413518B2 (en) CYP450 lipid metabolites reduce inflammation and angiogenesis
JP2016539098A (ja) 網膜の血管障害を治療又は予防する方法
EP2994197B1 (en) Pharmaceutical combination of an nsaid and atropine
Provost et al. Morphologic and electroretinographic phenotype of SR-BI knockout mice after a long-term atherogenic diet
WO2011097577A2 (en) Compositions and methods for treating or preventing retinal degeneration
Paiva et al. Licarin A as a novel drug for inflammatory eye diseases
Babizhayev et al. Novel intraocular and systemic absorption drug delivery and efficacy of N‐acetylcarnosine lubricant eye drops or carcinine biologics in pharmaceutical usage and therapeutic vision care
Chen et al. Vitamin K1 Alleviates Retinal Inflammation Following Acute Ocular Hypertension by Modulating Microglial Ferroptosis
CN115038434A (zh) 用于治疗角膜病变的生物分子
JP2022531484A (ja) 加齢性黄斑変性症を治療するための物質および方法
HK40080196A (en) Biomolecule for treatment of corneal pathologies
Tan Organelle Trafficking in Health and Disease of the Retinal Pigment Epithelium
Amitabh Lipid Profile In Diabetic Retinopathy In Type 2 Diabetic Mellitus
EP3648794A1 (en) Use of macroazapyridinophanes metal complexes in the treatment of diseases
JP2017132742A (ja) Ａβオリゴマー特異的抗体の新規薬理用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191010

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191010

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200908

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210308

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210511

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210910

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210910

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20211015

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20211019

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220121

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220208

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220225

R150 Certificate of patent or registration of utility model

Ref document number: 7037186

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250